Newsletter Vol. 1 Issue 1
Healthcare & Biological Sciences Research Association
Dear HBSRA Members,
Thank you for your interest and support in our organization. HBSRA now has over 4696 members from 45 countries. We are happy to launch our first newsletter for our Association. Here are some of the glimpses of our current and upcoming endeavors.
HBSRA has recently signed International collaborations with the following:
- Srishti International, Bangalore, (India)
- GTIS, Taiwan (Green Technology Invention Society, Taiwan)
- Tresorix Ltd. Mauritius
We would be glad to have MoUs and collaborations with your department/society/organization.
Singapore & Malaysia Conference
We have successfully organized our conferences in Singapore and Malaysia, which were held in May, June, & July 2016 at universities Rumah Kelab PAUM Clubhouse (Persatuan Alumni Universiti Malaya), Kuala Lumpur, Malaysia and Nanyang Technological University, Nanyang Executive Centre, Singapore with the support of Eurasia Research. In these conferences, around 168 colleagues participated across the globe. We would like to thank all our participants and our supporters of our conferences.
Prof. A.J. Halim
Lincoln University College, Petaling Jaya, Malaysia
Title: Learning from positive outcomes following cell based therapy
This underlying principle of “organospecificity” underpins historically stem cell transplantation for more than 80 years which uses young stem cells from animal sources. Currently genetically engineered specific organ cells from induced Precursor Stem Cells (iPSCs) are being studied for their safety and effectiveness and clinical trials have started for certain untreatable conditions. Since the early 20thcentury, proponents of cell therapy including Paul Niehans (father of cell therapy) and other European and Russian cell therapists have treated millions of patients using young organ cells of animal origin. Stem cell prescription is individualized based on the pathophysiology of the patient. Its revitalisation and rejuvenation effects have been legendary. The Malaysian group completed its seven years clinical studies on the use of fetal precursor stem cell xenotransplants in treating currently untreatable /no longer treatable diseases. These precursor cells from primary tissue cultures are derived from fetuses of closed colony rabbits bred in accordance to the regulations of the FDA (USA) and AAALAC. No genetic engineering is involved and these are administered without immunosuppression. More than 800 transplantations were carried out without any severe complications. We find the treatment to be safe. It is effective in treating Down syndrome, Autism, and Parkinson Disease and for other genetic disorders. What is much needed is research into the subcellular and molecular mechanisms using genomics, proteomics and peptidomics to uncover the pathways that give rise to the cellular defects and the mechanism by which cell therapy has led to improvement of patients. This “patient to bench approach “ research on positive outcomes may give us better understanding of cell based therapy.
Saad Sabbar Dahham
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pinang, Malaysia
Title: Natural Products and Cancer: Hope on the Horizon?
There is some truth to the old adage that the therapeutic use of natural products and their derivatives is as old as the human race. The ancient civilizations provided written evidences for the use of natural sources to treat various illnesses. In fact, the oldest description of medical document dated 4000 years ago, depicted on a Sumerian clay table with a list of the most valuable medicinal plants. The knowledge and historical experiences of medicinal plant have been passed from one generation to the next, interpreted as accumulative body and form the basis of traditional and modern medicine. According to the World Health Organization (WHO), about 80 % of population in the developing countries relies on traditional herbal medicine for primary health care needs. Recently, a wide range of plant-derived phytochemical components and their synthetic derivatives have been suggested for cancer treatment. Moreover, it has been estimated that 25 %-48 % of the currently approved therapies by the Food and Drug Administration (FDA) are derived from plants. As a researcher in EMAN Laboratory, USM University- Malaysia I had the opportunity to work on the several plant extracts, pure compounds and synthetic molecules towards different cancer cells, and what I found is that many natural products have the ability to target cancer cells selectively via inducing apoptosis or inhibiting angiogenesis process. With the potential benefits of natural products, we hope to be able to discover new compounds that may be therapeutically useful against carcinogenesis.
We are pleased to announce that distinguished colleagues Saad Sabbar Dahham and David Harris-Birtill, who have joined the conference as keynote speakers:
Universiti Sains Malaysia, Pinang, Malaysia
St Andrews, Scotland, UK